



# INTERNATIONAL SYMPOSIUM ON “FRONTIERS IN THERAPEUTIC ENGINEERING AND ANTIBODY TECHNOLOGIES”



## Event Report

DPSRU Innovation & Incubation Foundation (DIIF) in collaboration with Delhi Pharmaceutical Sciences & Research University (DPSRU) organized a Two-day International Symposium on “Frontiers in Therapeutic Engineering and Antibody Technologies”

**Venue:** Board Room, DPSRU, New Delhi

**Dates:** September 16–17, 2025

The International Symposium at DPSRU convened distinguished scientists, industry experts, and innovators for in-depth discussion and knowledge sharing on cutting-edge therapeutic engineering and antibody technologies. The two-day event fostered academic-industry partnerships, showcased advances in biologics, protein therapeutics and translational research strategies. The key objectives were:

- Facilitate cross-disciplinary knowledge exchange on therapeutic engineering and antibody technologies.
- Foster academia-industry partnerships and translational research networking.
- Encourage regulatory understanding and commercialization in biologics.
- Launch collaborative programs and research initiatives via MoUs.



### Day 1: September 16, 2025

Day 1 was started with Inauguration ceremony wherein, **Mr Sourabh Tiwari**, Program Lead, DIIF talked about the Vision of DIIF. This was followed by address about DPSRU by **Dr RC Khatri**, Off Registrar, DPSRU. The welcome address of Symposium was delivered by **Dr Meenakshi K Chauhan**, Director, DIIF. **Prof. Ravichandiran V**, Hon'ble Vice Chancellor, DPSRU, welcomed expert speakers, addressed the participants and shared his strategic vision for biotherapeutics research. The **Chief Guest, Mr. Chetan Gupta**, proud alumnus and Industry expert (Emcure) addressed the participants and shared his knowledge about the changing regulatory landscape of biologics in India.




The symposium commenced with our first expert, **Prof. Sachdev Sidhu** from University of Waterloo, Canada. He presented insights on large-scale engineering of modulators of protein networks. Then **Dr. Sachin Soni**, Founder-Third Eye Fund discussed investor perspectives on scientific innovation and commercialization. **Dr. Shane Miersch**, University of Waterloo, Canada explained multivalent antibody design for therapeutic applications. He emphasized the role of multivalent antibodies in improving the efficacy.

- In post lunch session, **Dr. C.N. Ramchand**, MagGenome Technologies covered preclinical evaluation of MAb therapeutics for AMD and diabetic retinopathy. **Ms. Bhawna Gupta**, Roche Pharmaceuticals spoke on regulatory aspects for biologics in India. The day ended with high tea and networking.

## Day 2: September 17, 2025

- **The day 2 commenced with Book Release:** “Freeze-drying Technology in Pharmaceutical and Biomedical Product Development,” co-edited by DPSRU faculty from Pharmaceutical Sciences: Dr Dalapathi Gogulothu, Dr Sumit Sharma, Dr Meenakshi Kanwar Chauhan, Published by Springer.



- The expert session was delivered on post-translational engineering of therapeutic devices by **Prof. C. Ronald Geyer**, University of Saskatchewan, Canada. **Prof. Azad K. Kaushik** delivered his talk on Structural design and perspectives of antibody-based therapeutics. **Prof. T. P. Singh** from AIIMS addressed the participants on Peptide inhibitor design using expression tags for drug discovery.
- Post lunch, the experts and Delegates toured DIIF, CRDTH, CPMP, and GMP facilities established as Centre of Excellence at DPSRU for translational research exposure. The scientific session by **Prof. Deepak T. Nair** from RCB, Faridabad shared recent advances in anti-SARS-CoV-2 antibody characterization.



The essence of the symposium was the **MoU signing ceremony between DPSRU and SIMISCO Biologics**, a breakthrough step towards significant academic-industry partnership milestone. Finally, towards the end, the Vote of Thanks was delivered by Prof. Geeta Aggarwal, Incharge DIIF. The program concluded with National Anthem and a Group photograph.



Overall, the International Symposium on “*Frontiers in Therapeutic Engineering and Antibody Technologies*” not only reinforced DPSRU’s role as a leader in pharmaceutical research and innovation but also laid a strong foundation for future collaborative research and technological advancements in therapeutic sciences. The program was coordinated by team from DIIF Dr Amanpreet Kaur, Dr Sumit Sharma, and Mr. Sourabh Tiwari.